 |
Video: What is a Stock Split?
|
 |
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co.'s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. According to our CTSO split history records, Cytosorbents has had 2 splits. | |
 |

Cytosorbents (CTSO) has 2 splits in our CTSO split history database. The first split for CTSO took place on October 02, 2007. This was a 1 for 100 reverse split, meaning for each 100 shares of CTSO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 10 share position following the split. CTSO's second split took place on December 05, 2014. This was a 1 for 25 reverse split, meaning for each 25 shares of CTSO owned pre-split, the shareholder now owned 1 share. For example, a 10 share position pre-split, became a 0.4 share position following the split.
When a company such as Cytosorbents conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CTSO split history from start to finish, an original position size of 1000 shares would have turned into 0.4 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cytosorbents shares, starting with a $10,000 purchase of CTSO, presented on a split-history-adjusted basis factoring in the complete CTSO split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/01/2015 |
|
End date: |
04/29/2025 |
|
Start price/share: |
$6.91 |
|
End price/share: |
$1.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-83.79% |
|
Average Annual Total Return: |
-16.63% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,621.37 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
10/02/2007 | 1 for 100 | 12/05/2014 | 1 for 25 |
|
 |